本帖最后由 老马 于 2013-3-13 13:43 编辑
; ^; i; m9 o0 G$ P5 q0 @& p$ J* f
8 `% s) n" r# H5 c# ~6 P7 g健择（吉西他滨）+顺铂+阿瓦斯汀
0 h* \- K6 z: I, T Gemzar +Cisplatin + Avastin& T; B$ A/ x0 I3 u. A
http://annonc.oxfordjournals.org/content/21/9/1804.full
O" B/ X) @, {6 q) D) i6 R5 oOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) : w4 @' |- s! y! y# W
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, n4 H! X, }& l9 [1 n( s aResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; M; w4 ~& [4 ]1 ~" f5 _4 L# H6 c
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 893)
2 Z/ v3 }1 A# ]/ H# Y6 `华为网盘附件：" V+ e, P+ M6 i
【华为网盘】ava.JPG
9 q4 K% C: n- w+ y; R7 H |
显身卡
